Samsung Valsartan 80 mg Tablet
Valsartan 80mg
Tablet · Prescription medication
Samsung Pharmaceutical Co., Ltd.
MFDS item code 201904770 · Approved 2019.07.16
This product's status changed to Expired on 2024.07.16. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension, reduction in the risk of death after myocardial infarction, and treatment of heart failure
This medication is used to treat essential hypertension and heart failure. It is particularly effective for heart failure patients who are intolerant to ACE inhibitors. Additionally, it helps reduce the risk of mortality in stable patients with left ventricular dysfunction or heart failure following a myocardial infarction. Thus, it plays an important role in improving the management of cardiovascular diseases.
1. Essential hypertension Take with water during or between meals. It is recommended that you take this medicine at the same time each day (e.g., in the morning), if possible. 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be administered concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: For patients who are volume depleted (e.g., patients taking high-dose diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily, and do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy of this medicine with an ACE inhibitor and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily. Over the following weeks, increase the dose, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with ACE inhibitors is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary if creatinine clearance is 10 mL/min or greater. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: For patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age. The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus, especially in the second and third trimesters of pregnancy, so it should be stopped immediately if pregnancy is confirmed. Women who are pregnant or may become pregnant, as well as nursing mothers, should not take this medication. Patients with severely impaired liver function or certain liver diseases should generally avoid this medication. It should also not be administered to patients with a history of angioedema or severe kidney impairment. For diabetic patients with moderate or severe renal impairment, this medication should not be taken in conjunction with certain other drugs. Elderly patients, those with hyperkalemia, and patients with mild to moderate liver impairment should use this medication with particular caution. Patients with heart valve disease or cardiovascular diseases, as well as those with volume depletion, should also use it carefully. Blood pressure may drop rapidly with initial use of this medication, so if symptoms of hypotension occur, immediate consultation with a healthcare professional is necessary. When used in combination with other antihypertensives or diuretics, caution should be exercised for hypotension or changes in renal function, and regular blood pressure and blood tests should be performed. There is an increased risk of elevated potassium levels, so caution is warranted when taken with potassium supplements or potassium-sparing diuretics. This medication is not recommended for children or adolescents as safety and effectiveness have not been established. Dizziness or drowsiness may occur while on this medication, so caution is advised when driving or operating machinery. In cases of overdose, severe hypotension or altered consciousness may occur, necessitating immediate medical care. This medication should be stored out of reach of children and should not be transferred to other containers.
headache
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture, ideally in a cool place below 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness and prevent degradation.
Pink round film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Valsartan 80mg
Tablet · Prescription medication
Samsung Pharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.